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Abstract
Background: Pulmonary hypertension is associated with a worse prognosis after cardiac transplantation. The pulmonary 
hypertension reversibility test with sodium nitroprusside (SNP) is associated with a high rate of systemic arterial 
hypotension, ventricular dysfunction of the transplanted graft and high rates of disqualification from transplantation.
Objective: This study was aimed at comparing the effects of sildenafil (SIL) and SNP on hemodynamic, neurohormonal 
and echocardiographic variables during the pulmonary reversibility test.
Methods: The patients underwent simultaneously right cardiac catheterization, echocardiography, BNP measurement, 
and venous blood gas analysis before and after receiving either SNP (1 – 2 µg/kg/min) or SIL (100 mg, single dose). 
Results: Both drugs reduced pulmonary hypertension, but SNP caused a significant systemic hypotension (mean blood 
pressure - MBP: 85.2 vs. 69.8 mm Hg; p < 0.001). Both drugs reduced cardiac dimensions and improved left cardiac 
function (SNP: 23.5 vs. 24.8%, p = 0.02; SIL: 23.8 vs. 26%, p < 0.001) and right cardiac function (SIL: 6.57 ± 2.08 vs. 
8.11 ± 1.81 cm/s, p = 0.002; SNP: 6.64 ± 1.51 vs. 7.72 ± 1.44 cm/s, p = 0.003), measured through left ventricular 
ejection fraction and tissue Doppler, respectively. Sildenafil, contrary to SNP, improved venous oxygen saturation, 
measured on venous blood gas analysis.
Conclusion: Sildenafil and SNP are vasodilators that significantly reduce pulmonary hypertension and cardiac geometry, 
in addition to improving biventricular function. Sodium nitroprusside, contrary to SIL, was associated with systemic 
arterial hypotension and worsening of venous oxygen saturation. (Arq Bras Cardiol. 2012; [online].ahead print, PP.0-0)
Keywords: Pulmonary Hypertension; Sildenafil; Sodium Nitroprusside; Tecidual Doppler; Cardiac Transplant.
Introduction
Pulmonary hypertension (PH) in cardiac transplantation 
candidates with chronic heart failure is a well-established risk 
factor for early death due to right ventricular or biventricular 
dysfunction of the transplanted graft1. To minimize the failure of 
donated organs, those patients are routinely submitted to the PH 
reversibility test and preoperative right cardiac catheterization, 
aiming at measuring the responsiveness of pulmonary pressure, 
and its hemodynamic variables, to vasodilators 2-4.
Sodium nitroprusside (SNP) is the vasodilator routinely used, 
but systemic arterial hypotension is a common and limiting side 
effect. In patients with chronic heart disease, the borderline blood 
pressure and ventricular dysfunction reduce the compensatory 
capacity of the cardiovascular system to maintain systemic 
arterial blood pressure stable, and hemodynamic instabilities 
are associated with high indices of heart decompensation and 
patient’s disqualification from transplantation. 
Sildenafil (SIL) is a potent and selective inhibitor of 
phosphodiesterase type 5 (PDE-5), the enzyme responsible 
for cGMP degradation. That inhibition determines an increase 
in the cytosolic cGMP concentration and consequent vascular 
smooth muscle relaxation, resulting in vasodilation. As a PDE-5 
inhibitor, SIL has direct effects on pulmonary circulation and 
right ventricular myocardium (Figure 1), promoting, in addition 
to a reduction in pulmonary vascular resistance (PVR), a direct 
and indirect increase in cardiac output5. 
The effects of SIL on the cardiovascular system of patients 
with heart failure and PH have been demonstrated with both 
acute and chronic uses. Gómez-Sánchez et al.6 and Freitas Jr. 
et al.7 have shown that a single dose of 100 mg of sublingual 
SIL was effective and safe in reducing pulmonary pressure 
during the PH reversibility test before cardiac transplantation, 
without significantly interfering with systemic arterial blood 
pressure. However, during prolonged administration, Katz 
et al.8 have shown that SIL causes endothelium-dependent 
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Figure 1 – Pathophysiological changes in the pulmonary circulation and right ventricular myocardium of patients with pulmonary hypertension. The inhibition of 
phosphodiesterase type 5 (PDE-5) by sildenafil has a positive inotropic effect on the right ventricle and delays the pulmonary artery remodeling process. 
* RV: right ventricle; CO: cardiac output; BNP: brain natriuretic peptide; NO: nitric oxide; ANP: atrial natriuretic peptide; cGMP: cyclic guanosine monophosphate; 
PDE3: phosphodiesterase type 3; cAMP: cyclic adenosine monophosphate. (Adapted from Archer SL et al., NEJM. 2009).
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vasodilation and improves physical capacity, measured by use 
of the six-minute walk test. 
Thus, an ideal vasodilator would serve not only to test vascular 
responsiveness of pulmonary pressure, but would not interfere 
negatively with systemic circulation, would enhance right cardiac 
output, and would maintain a sustained reduction in PH. 
The major objective of this study was to compare the 
acute hemodynamic effects of SIL and SNP on PH of 
heart transplantation candidates with advanced heart 
failure. Its second objective was to assess the effects of 
two vasodilators on cardiac geometry, microcirculation, 
and neurohormonal variables. 
Methods
This cross-sectional, prospective and randomized study was 
performed at the Heart Failure and Transplantation Clinical 
Unit of the Instituto do Coração of the Hospital das Clínicas of 
the Medical School of the Universidade de São Paulo (InCor 
– HCFMUSP), from June 2006 to June 2009. Patients meeting 
the inclusion criteria were included in the study randomly. The 
study protocol was approved by the Scientific Committee of 
the Instituto do Coração – InCor (SDC 2698/05/118) and by 
the Ethics Committee on Scientific Research of the Hospital 
das Clínicas of the Medical School of the Universidade de São 
Paulo (935/05). The patients or their guardians (for children 
and adolescents) provided written informed consent.
Patients
The study population consisted of patients from the Heart 
Failure Outpatient Clinic of the InCor-HCFMUSP, who had 
moderate or severe left ventricular dysfunction [ejection 
fraction (EF) < 45%], NYHA functional class III or IV heart 
failure and formal indication for cardiac transplantation, 
according to the International Society for Heart and Lung 
Transplantation guidelines (ISHLT)9 and the Brazilian Society 
of Cardiology for Heart Transplantation guidelines10. 
Patients with the following characteristics were excluded 
from the study: arteriovenous shunts; associated pulmonary 
disease; use of vasoactive drugs; and hemodynamic instability.
 
Study design
After undergoing right heart catheterization and two-
dimension Doppler echocardiography simultaneously, as part 
of the routine preoperative assessment for heart transplantation, 
the patients were selected by this study’s author, according to 
the inclusion and exclusion criteria already described.
Then, general clinical data of all patients were recorded, 
and venous blood samples were also collected from the 
pulmonary artery for the analysis of biochemical variables. 
Once the baseline tests were performed, the patients were 
randomized to receive either SNP or SIL, at standardized 
doses. A second collection of clinical, hemodynamic, 
echocardiographic and biochemical data was performed after 
a predetermined period of time for each group (Figure 2).
Sildenafil was orally administered during fasting at the 
single dose of 100 mg (two tablets of 50 mg), and, after 
60 minutes, the time interval considered ideal to obtain the 
highest blood concentration of that drug, a second round of 
tests was performed8,9. 
The SNP solution, consisting of 50 mg of SNP into 
250 mL of 5% glucose solution, was administered by use of a 
continuous intravenous infusion pump, at the velocity of 1 µg/
kg/min. After 15 minutes, the patients underwent non-invasive 
measurement of their systemic arterial blood pressure and of 
their systolic pressure of the pulmonary artery and its variables 
through right heart catheterization. The criteria for interrupting 
the administration of SNP were as follows: systemic arterial 
hypotension (systolic blood pressure (SBP) ≤ 85 mm Hg) and/or 
Figure 2 – Study design.
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appropriate reduction in PH (pulmonary artery systolic pressure 
– PASP < 50 mm Hg; PVR < 3 Wood units; and transpulmonary 
gradient - TPG < 15 mm Hg). When the interruption criteria 
were not reached, the infusion velocity was increased to 
2 µg/kg/min, and new measurements of the hemodynamic 
parameters were taken every 15 minutes, with a gradual and 
proportional increase in the drug administration velocity. 
Hemodynamic variables
Pressure readings were taken by use of the Swan-Ganz 
catheter in the following sites: right atrium (mean pressure); 
right ventricle (systolic, diastolic and mean pressure); and 
pulmonary artery (systolic, diastolic and mean pressure). The 
pulmonary artery occlusion pressure or mean pulmonary 
capillary wedge pressure (PCWP) was also recorded. 
Pulmonary and systemic cardiac output, the later 
assumed as equal to the first, was measured by using the 
thermodilution method. 
Based on those measures, PVR and systemic vascular 
resistance (SVR) were determined, in addition to TPG. 
Echocardiographic variables
Echocardiographic assessment was performed by using the 
HDI 5000 device (Philips Medical System, Andover, MA, USA), 
equipped with a broadband 4-2-MHz transducer.
Echocardiography was performed by the same skilled 
examiner at the heart catheterization laboratory, simultaneously 
with the hemodynamic study.
Assessment of the left and right cavities allowed the 
determination of the atrial and ventricular diameters, in 
addition to left ventricular EF (LVEF). The right atrial and 
right ventricular volumes were measured in the apical four-
chamber view, using the area-length method, during systole 
and diastole. Right ventricular function was estimated by 
the tricuspid annular plane systolic excursion (TAPSE, cm/s) 
using tecidual Doppler.
Biochemical variables
Venous blood samples were collected from the pulmonary 
artery during right cardiac catheterization, and the following were 
measured: brain natriuretic peptide and venous blood gas analysis. 
Statistical Analysis
Initially, the variables assessed were tested regarding their 
adherence to normal distribution (Gaussian) for determining 
the adequate statistical test to be used. Only the p values 
< 0.05 were considered statistically significant, with a 95% 
confidence interval.
Comparison between groups
For comparing the baseline characteristics of both groups, 
the qualitative variables (gender, etiology of the underlying 
disease, and heart failure functional class) were assessed by 
using the chi-square test, and presented in a contingency table 
containing absolute (n) and relative (%) frequencies.
The quantitative variables were assessed according to 
the normality of distribution. Those with a non-normal 
distribution (mean dose of digoxin, spironolactone, losartan 
and hydrochlorothiazide) were assessed based on the Mann-
Whitney U test, and those with normal distribution (all other 
variables) were assessed by using the independent Student t test.
Analysis of each group before and after the administration 
of vasodilators
The hemodynamic, echocardiographic and biochemical 
quantitative variables had Gaussian distribution, and their 
means were compared by use of Student t test for paired data.
Results
Of the 30 patients selected according to the established 
criteria, one was excluded due to atrial fibrillation during 
echocardiography. The 29 patients effectively participating 
in the study had a mean age of 49.1 ± 14.9 years, and most 
were males (62%). Tables 1 and 2 synthesize the baseline 
characteristics of the population studied.
Hemodynamic variables
The group receiving SIL showed a significant reduction in 
PVR (4.26 ± 2.65 vs. 1.94 ± 1.39 Wood units; p < 0.001) 
and an increase in cardiac output (3.64 ± 0.81 vs. 4.31 ± 
0.81 L/min; p = 0.003). Those effects were not accompanied 
by negative systemic repercussions, as shown in Table 3. 
The group receiving SNP showed a different hemodynamic 
response. A moderate reduction in PH was observed (PVR: 
4.52 ± 3.15 vs. 4.03 ± 3.13 Wood units; p = 0.2), but no 
interference with cardiac output (3.64 ± 1.06 vs. 3.86 ± 
1.19 L/min; p = 0.2). Unlike the group on SIL, patients on SNP 
showed important systemic repercussions, such as systemic 
hypotension SBP: 85.29 ± 13.1 vs. 69.86 ± 13.48 mmHg; 
p < 0.001) and increased heart rate (66.79 ± 8.22 vs. 73.79 
± 12.42 bpm; p = 0.001).
Echocardiographic variables
The acute administration of SIL was associated with 
significant reductions in the mean area of the right atrium (24.4 
± 6.33 vs. 21.6 ± 5.46 mm2; p = 0.008) and left ventricle 
(29.4 ± 5.63 vs. 23.8 ± 5.57 mm2; p < 0.001), as shown in 
Figure 3. The reduction in cardiac geometry was accompanied 
by an increase in the left and right cardiac functions, measured 
by LVEF (23.87 ± 8 vs. 26.07 ± 7.46%; p = 0.001) and TAPSE: 
6.57 ± 2.08 vs. 8.11 ± 1.81 cm/s; p = 0.002), respectively, 
shown in Figure 4. 
The group receiving SNP as vasodilator, however, also 
showed a significant reduction in the right ventricular area 
(29.21 ± 5.24 vs. 25.79 ± 4.9 mm2; p = 0.007), but only a 
tendency towards reduction in the right atrial area (29.71 ± 
6.52 vs. 27.86 ± 6.18 mm2; p = 0.08). Nevertheless, SNP 
was associated with an improvement in LVEF (23.57 ± 4.69 
vs. 24.86 ± 5.64 %; p = 0.02) and TAPSE (6.64 ± 1.51 vs. 
7.72 ± 1.44 cm/s; p = 0.003).
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Table 1 – Baseline demographic characteristics of the patients studied 
All Sildenafil Sodium nitroprusside p
Patients 29 15 14 NS
Age, years (mean ± sd) 49.10 ± 14.9 49.73 ± 11.17 48.42 ± 17.45 0.08
Sex, male (%) 18 (62%) 11 (73.3%) 7 (50%) 0.19
NYHA functional class n (%)
III
IV
11 (37.9%)
18 (62.1%)
05 (33.3%)
10 (66.4%)
06 (42.8%)
08 (57.2%) 0.01
Etiology n (%)
Ischemic
Idiopathic
Chagas’ disease
Hypertensive
Other
10 (34.5%)
06 (20.7%)
08 (27.5%)
02 (7%)
03 (10.3%)
05 (33.3%)
02 (13.3%)
05 (33.3%)
02 (13.3%)
01 (6.8%)
05 (35.7%)
04 (28.5%)
03 (21.5%)
0
02 (14.3%)
0.29
Drug (mean dose ± sd)
Carvedilol (mg/day)
Losartan (mg/day)
Spironolactone (mg/day)
Digoxin (mg/day)
Furosemide (mg/day)
Hydrochlorothiazide (mg/day)
35.9 ± 24.5
73.2 ± 33.3
22.4 ± 7.7
0.18 ± 0.06
80 ± 40.3
13.2 ± 17
41.6 ± 27.8
71.6 ± 32.5
21.6 ± 8.7
0.15 ± 0.07
86.6 ± 45.1
13.3 ± 18.6
29.9 ± 19.7
75 ± 35.3
23.2 ± 6.6
0.1 ± 0.04
72.8 ± 34.7
13.1 ± 15.9
0.20
0.79
0.60
0.03
0.36
0.97
Table 2 – Baseline hemodynamic, echocardiographic and biochemical variables in both groups 
Variables Sildenafil Sodium nitroprusside p
Hemodynamics
MBP (mm Hg) 80.00 ± 11.22 85.29 ± 13.10 0.252
HR (bpm) 63.53 ± 10.80 66.79 ± 8.22 0.372
PASP (mm Hg) 61.07 ± 13.35 64.50 ± 14.62 0.514
MRAP (mm Hg) 14.27 ± 3.65 16.57 ± 8.38 0.340
CO (L/min) 3.64 ± 0.81 3.64 ± 1.06 0.997
TPG (mm Hg) 14.67 ± 6.74 14.36 ± 8.38 0.913
PVR (Wood units) 4.26 ± 2.65 4.52 ± 3.15 0.814
SVR (dynes.s.cm-5) 1502.47 ± 375.71 1620.34 ± 597.24 0.24
Echocardiographic
LVDD (mm) 73.87 ± 13.09 71.86 ± 13.55 0.688
LVEF (%) 23.87 ± 8.00 23.57 ± 4.69 0.905
RA area (mm2) 24.40 ± 6.33 29.71 ± 6.52 0.035
RV area (mm2) 29.40 ± 5.63 29.21 ± 5.24 0.928
TAPSE (cm/s) 6.57 ± 2.08 6.64 ± 1.51 0.926
Biochemical
pH 7.41 ± 0.02 7.38 ± 0.04 0.017
pO2 (mmHg) 29.78 ± 3.34 35.31 ± 4.17 0.001
SvO2 (%) 49.25 ± 8.74 59.19 ± 10.10 0.008
BNP (pg/mL) 751.20 ± 598.02 988.29 ± 500.31 0.259
MBP: mean systemic blood pressure; HR: heart rate; PASP: pulmonary artery systolic pressure; MRAP: mean right atrial pressure; CO: cardiac output; TPG: 
transpulmonary gradient; PVR: pulmonary vascular resistance; SVR: systemic vascular resistance; LVDD: left ventricular end-diastolic diameter; LVEF: left 
ventricular ejection fraction; RA area: right atrial area; RV area: right ventricular area; TAPSE: tricuspid annular plane systolic excursion.
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Table 3 – Pulmonary and systemic hemodynamic effects of both vasodilators 
Variables Before SIL After SIL p Before SNP After SNP p
MBP (mm Hg) 80 ± 11.2 76.4 ± 9 0.054 85.2 ± 13.1 69.8 ± 13.4 < 0.001
HR (bpm) 63.5 ± 10.8 63.6 ± 10.5 0.902 66.7 ± 8.2 73.7 ± 12.4 0.001
PVR (Wood units) 4.26 ± 2.65 1.94 ± 1.39 < 0.001 4.52 ± 3.15 4.03 ± 3.13 0.2
CO (L/min) 3.64 ± 0.81 4.31 ± 0.81 0.003 3.64 ± 1.06 3.86 ± 1.19 0.2
PCWP (mm Hg) 23.6 ± 6.4 23.5 ± 7.3 0.964 28.5 ± 7.5 23.6 ± 9.3 0.001
MRAP (mm Hg) 14.2 ± 3.6 11.6 ± 3.9 0.06 16.5 ± 8.3 15.5 ± 8.7 0.404
SVR (dynes.s.cm-5) 1502.4 ± 375.7 1241.6 ± 298.9 0.006 1620.3 ± 597.2 1204.5 ± 545.2 0.004
SIL: sildenafil; SNP: sodium nitroprusside; MBP: mean systemic blood pressure; HR: heart rate; PVR: pulmonary vascular resistance; CO: cardiac output; PCWP: 
pulmonary capillary wedge pressure; MRAP: mean right atrial pressure; SVR: systemic vascular resistance.
Figure 3 – Significant reductions (p < 0.05) in the right atrial and ventricular areas after administration of sildenafil and sodium nitroprusside. 
* RA: right atrium; RV: right ventricle; SIL: sildenafil; SNP: sodium nitroprusside.
SIL (RA area) SNP (RA area) SIL (RV area) SNP (RV area) 
Before After
Figure 4 – Increase in left ventricular ejection fraction (A) and S’ (B) after administration of sildenafil and sodium nitroprusside. 
*LVEF: left ventricular ejection fraction; TAPSE: tricuspid annular plane systolic excursion; SIL: sildenafil; SNP: sodium nitroprusside.
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Biochemical variables
SIL associated with an improvement in pO2 (29.78 ± 
3.34 vs. 34.36 ± 2.94 mm Hg; p < 0.001) and in venous 
oxygen saturation (SvO2: 49.25 ± 8.74 vs. 58.92 ± 6.84 %; 
p < 0.001), as shown in Figure 5. This group also showed a 
significant reduction in mean pCO2 (44.25 ± 6.61 vs. 41 ± 
6.11 mm Hg; p < 0.001) and a decrease in the serum levels of 
BNP (751.2 ± 598.01 vs. 622.27 ± 497.08 pg/mL; p = 0.15), 
but with no statistical significance. 
The SNP group showed different results as follows: 
worsening of pO2 (35.31 ± 4.17 vs. 31.34 ± 3.94 mm Hg; 
p < 0.001) and SvO2 (59.19 ± 10.1 vs. 53.58 ± 9.36%; 
p < 0.001); and no interference in pCO2 (45.18 ± 3.69 
vs. 44.91 ± 4.29 mm Hg; p = 0.49). A tendency towards a 
reduction in the serum levels of BNP was observed (988.29 
± 500.31 vs. 836 ± 365.31 pg/mL; p = 0.07).
Discussion
Pulmonary hypertension in patients with heart failure, 
although considered an important comorbidity with potential 
risk for death after heart transplantation, has not been widely 
explored, and studies on its acute perioperative management 
are scarce. 
Some studies have shown that the PH reversibility test 
with SNP is associated with high indices of resistant PH and 
systemic hypotension, situations that contraindicate heart 
transplantation11. That group of patients had a lower survival 
rate (~29%) in the first 30 days following transplantation as 
compared with patients who had no arterial hypotension 
11-13 (~67%). 
In that context, SIL has emerged as a feasible option, 
because it promotes selective and sustained pulmonary 
vasodilation, with minimum systemic effects14-16. However, 
the use of SIL in patients with left ventricular dysfunction 
is recent and uncertain, which emphasizes the importance 
of this study.  
Figure 5 – Improvement and worsening of venous oxygen saturation (SvO2) after using sildenafil (p < 0.001) and sodium nitroprusside (p < 0.001), respectively. 
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The first limitation of this study is its open design, because 
two drugs with different administration routes were compared, 
resulting in loss of the double-blind study characteristic of 
avoiding prejudgment.
The epidemiological profile of the population sample 
studied is in accordance with that of the literature, most 
patients being males (62%) and with heart failure of ischemic 
etiology (34.5%). 
Our study showed that SIL and SNP were effective in reducing 
PH of candidates for heart transplantation, but they had different 
effects on systemic circulation. Such findings had already been 
shown before, when we evidenced that the administration of a 
single dose of SIL reduced PH, increased cardiac output, and did 
not interfere with systemic blood pressure7. 
The effects of vasodilators on cardiac geometry and 
function were extremely important. Both drugs reduced 
the mean diameters of the right cardiac chambers and 
concomitantly improved biventricular function. The change 
in cardiac dimension and function might be secondary to the 
reduction in afterload, but the direct effects of SIL on right 
ventricular inotropism do not exclude the hypothesis of an 
additional action on myocardial performance. Such findings 
support the hypothesis that SIL and SNP act on the acute and 
reverse cardiac remodeling process. That expression has been 
widely used, even without molecular and histopathological 
data, as demonstrated in some studies. Bacal et al.17 have 
assessed the normalization of right ventricular function and 
cardiac remodeling after heart transplantation by using only 
cardiac magnetic resonance imaging. Similarly, Yu et al.18 
and Ferrazzi et al.19 have already used the term ‘reverse 
remodeling’ to designate reductions in the mean ventricular 
diameters and increase in systolic function, obtained from 
resynchronization therapy and/or ventriculoplasty. 
Another controversial aspect regarding two-dimension 
echocardiographic assessment is that the right ventricular 
volume and systolic function quantification remains a 
challenge, because of the complex geometry of that chamber 
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and the lack of standardized methods for its evaluation; 
however, on clinical practice, they are usually estimated 
qualitatively. The assessment of systolic function on tissue 
Doppler (TAPSE) was the most accurate and available way20,21 
to satisfy the initial objectives of this study.
When assessing the biochemical variables, the initial 
objective was to correlate the central cardiovascular effects 
with neurohormonal and microcirculatory markers, such 
as BNP and venous blood gas analysis, respectively. The 
improvement in the venous oxygenation indices after the 
administration of SIL, contrary to that of SNP, was due to the 
balanced reduction in SVR and PVR. The BNP levels showed 
no significant changes, maybe because of the short time 
interval between the two collections. 
Conclusion
Both SIL and SNP significantly reduce PH in patients 
with chronic left ventricular dysfunction, being associated 
with a reduction in cardiac geometry and improvement 
in biventricular function. Only SIL improved the rates of 
peripheral oxygenation, with no interference with systemic 
blood pressure. 
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